Medivir AB (publ) (STO:MVIR)

Market Cap	864.03M +227.8%
Revenue (ttm)	8.50M +144.0%
Net Income	-94.40M
EPS	-0.66
Shares Out	538.67M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,582,025
Average Volume	15,287,849
Open	1.670
Previous Close	1.710
Day's Range	1.550 - 1.724
52-Week Range	0.340 - 2.195
Beta	-0.05
RSI	66.90
Earnings Date	Feb 18, 2026

About Medivir AB

Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Sweden, the Nordic region, rest of Europe, and internationally. The company offers Xerclear for the treatment of labial herpes under the Zoviduo name; and Olysio to treat hepatitis C. It also develops Remetinostat, a histone deacetylase (HDAC) inhibitor that has completed Phase II studies for treating mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL), basal cell carcinoma (BCC), and squamous cell carcinoma (SCC); MIV-711...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1987
• Employees: 10
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: MVIR

Financial Performance

In 2025, Medivir AB's revenue was 8.50 million, an increase of 143.97% compared to the previous year's 3.48 million. Losses were -94.40 million, -23.45% less than in 2024.